Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

Alicia B Carver; Autumn D Zuckerman; Joshua DeClercq; Leena Choi; Cody A Chastain

doi:10.1093/ofid/ofaa569

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

Open Forum Infect Dis. 2020 Nov 26;7(12):ofaa569. doi: 10.1093/ofid/ofaa569. eCollection 2020 Dec.

Authors

Alicia B Carver¹, Autumn D Zuckerman¹, Joshua DeClercq², Leena Choi², Cody A Chastain³

Affiliations

¹ Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
² Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
³ Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Abstract

Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.

Keywords: antiviral agents; hepatitis C virus; rapid virologic response; sustained virologic response; viral load.